secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2021-07-26T23:59:59+00:00
Accession:  0001193125-21-223656
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics appoints Kristian Humer as CFO and CBO, effective July 26, 2021
--------------------------------------------------------------------------------

- Mr. Humer will receive an annual base salary of $530,000, a sign-on bonus of $400,000, and a target bonus of 45% of base salary.
- He received an initial equity grant of options to purchase 360,000 shares, vesting over four years.
- Mr. Humer previously served as Managing Director in the Global Healthcare team at Citigroup Inc.
- The inducement grant was approved by a majority of independent directors in accordance with Nasdaq Listing Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/0001193125-21-223656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/d182412d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-223656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer